Published in J Antimicrob Chemother on January 01, 1984
Fluoroquinolone antimicrobial agents. Clin Microbiol Rev (1989) 6.45
The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother (1985) 6.44
Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother (1984) 3.35
Pharmacokinetics and tissue penetration of enoxacin. Antimicrob Agents Chemother (1984) 2.79
Pharmacokinetics and tissue penetration of orally administered lomefloxacin. Antimicrob Agents Chemother (1988) 1.85
Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob Agents Chemother (1991) 1.50
Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother (1992) 1.25
Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections. Antimicrob Agents Chemother (1985) 1.11
Treatment of genitourinary tract infections with fluoroquinolones: activity in vitro, pharmacokinetics, and clinical efficacy in urinary tract infections and prostatitis. Antimicrob Agents Chemother (1989) 1.10
In vitro susceptibility of pathogenic Vibrio species to norfloxacin and six other antimicrobial agents. Antimicrob Agents Chemother (1985) 1.02
Gemfibrozil enhances the listeriacidal effects of fluoroquinolone antibiotics in J774 macrophages. J Exp Med (1992) 1.01
Norfloxacin penetration into human renal and prostatic tissues. Antimicrob Agents Chemother (1985) 0.91
Comparative effects of enoxacin and norfloxacin on human colonic microflora. Antimicrob Agents Chemother (1987) 0.88
Antibiotic-containing polymers for localized, sustained drug delivery. Adv Drug Deliv Rev (2014) 0.80
In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. Infection (1986) 0.78
[Enoxacin concentration in seminal fluid, in prostate secretions and in prostatic adenoma tissue following oral administration or intravenous infusion]. Infection (1989) 0.78
Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers. Antimicrob Agents Chemother (1990) 0.76
Relationship of quantitative structure and pharmacokinetics in fluoroquinolone antibacterials. World J Gastroenterol (2007) 0.75
The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. Infection (1986) 0.75
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother (1983) 21.48
Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother (1983) 8.82
The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics. J Infect Dis (1980) 8.40
General practice fundholding. BMJ (1990) 6.43
National survey of hospital patients. BMJ (1994) 6.28
HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin. Antimicrob Agents Chemother (1978) 4.74
LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics. Antimicrob Agents Chemother (1979) 4.52
Antimicrobial resistance. Is a major threat to public health. BMJ (1998) 4.18
Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J (Clin Res Ed) (1986) 4.16
The pharmacokinetics and tissue penetration of ofloxacin. J Antimicrob Chemother (1984) 4.15
Functional anatomy of a common semantic system for words and pictures. Nature (1996) 4.14
Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin. Antimicrob Agents Chemother (1980) 4.07
Activity of azlocillin and mezlocillin against gram-negative organisms: comparison with other penicillins. Antimicrob Agents Chemother (1978) 3.68
Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (1998) 3.58
The anatomy of phonological and semantic processing in normal subjects. Brain (1992) 3.41
Rapid diagnosis of Campylobacter-associated gastritis. Lancet (1985) 3.38
In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother (1997) 3.22
Association of Helicobacter pylori infection with coronary heart disease. Study shows association between H pylori infection and hypertension. BMJ (1996) 3.00
Mupirocin resistance. Lancet (1991) 2.88
Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents. Antimicrob Agents Chemother (1985) 2.85
Pharmacokinetics of intravenously administered ciprofloxacin. Antimicrob Agents Chemother (1984) 2.83
Pharmacokinetics and tissue penetration of enoxacin. Antimicrob Agents Chemother (1984) 2.79
Exacerbation of pain by anxiety is associated with activity in a hippocampal network. J Neurosci (2001) 2.68
Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother (1999) 2.64
Local surveillance of antimicrobial resistance. Synercid Resistance Surveillance Group. Lancet (1998) 2.60
In vitro study of clavulanic acid in combination with penicillin, amoxycillin, and carbenicillin. Antimicrob Agents Chemother (1978) 2.58
Reward circuitry activation by noxious thermal stimuli. Neuron (2001) 2.56
Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds. Antimicrob Agents Chemother (1980) 2.51
The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. J Antimicrob Chemother (1995) 2.49
Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother (1981) 2.48
In vitro activity of Ro 15-8074 and Ro 19-5247, two orally administered cephalosporin metabolites. Antimicrob Agents Chemother (1986) 2.45
Comparison of the modified Stokes' method of susceptibility testing with results obtained using MIC methods and British Society of Antimicrobial Chemotherapy breakpoints. J Antimicrob Chemother (1998) 2.42
MRI in schistosomiasis of conus medullaris and lumbar spinal cord. Lancet (1993) 2.40
Mycobacterium chelonei isolation from broncho-alveolar lavage fluid and its practical implications. J Hosp Infect (1990) 2.37
A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother (1997) 2.37
Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins. J Antimicrob Chemother (1980) 2.35
Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J (1990) 2.33
Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum (1999) 2.22
Prevalence and clinical correlates of bronchoreversibility in severe emphysema. Eur Respir J (2009) 2.18
Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration. Antimicrob Agents Chemother (1982) 2.12
Early and late weight gain following smoking cessation in the Lung Health Study. Am J Epidemiol (1998) 2.10
In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J Antimicrob Chemother (1990) 2.09
Comparison of the in vitro activity of Bay k 4999 and piperacillin, two new antipseudomonal broad-spectrum penicillins, with other beta-lactam drugs. Antimicrob Agents Chemother (1978) 2.07
In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents. Antimicrob Agents Chemother (1986) 2.04
In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents. J Antimicrob Chemother (1984) 2.01
Prophylactic use of cephazolin against wound sepsis after cholecystectomy. Br Med J (1977) 1.97
Reproducibility of random amplified polymorphic DNA (RAPD) analysis among laboratories. PCR Methods Appl (1993) 1.97
Clinical and laboratory investigations on ticarcillin, an anti-pseudomonal antibiotic. Chemotherapy (1974) 1.97
Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone. Antimicrob Agents Chemother (1987) 1.96
Commercially available fluorescein-conjugated monoclonal antibody for determining the in vitro activity of antimicrobial agents against Chlamydia trachomatis. Eur J Clin Microbiol (1987) 1.93
Rapid diagnosis of Campylobacter pyloridis gastritis. Lancet (1986) 1.92
The cortical localization of the lexicons. Positron emission tomography evidence. Brain (1992) 1.91
Activity of the cefotaxime (HR756) desacetyl metabolite compared with those of cefotaxime and other cephalosporins. Antimicrob Agents Chemother (1980) 1.87
The comparative pharmacokinetics of five quinolones. J Antimicrob Chemother (1986) 1.86
Use of antibiotics. Penicillins. Br Med J (1978) 1.85
Bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions. J Antimicrob Chemother (1991) 1.85
Pharmacokinetics and tissue penetration of orally administered lomefloxacin. Antimicrob Agents Chemother (1988) 1.85
The pharmacokinetics of LY127935, a broad spectrum oxa-beta-lactam. J Antimicrob Chemother (1980) 1.85
Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob Agents Chemother (1992) 1.84
Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother (2001) 1.84
Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents Chemother (1992) 1.80
Ceftazidime--a new extended-spectrum cephalosporin. Lancet (1982) 1.79
The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin. J Antimicrob Chemother (1989) 1.75
Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels. Antimicrob Agents Chemother (1980) 1.75
Bacteroides fragilis and HR 756. J Antimicrob Chemother (1979) 1.73
Temocillin, in-vitro activity and the pharmacokinetics and tissue penetration in healthy volunteers. J Antimicrob Chemother (1982) 1.70
Ro 13-9904: A cephalosporin with a high degree of activity and broad antibacterial activity: an invitro comparative study. J Antimicrob Chemother (1980) 1.68
The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. J Antimicrob Chemother (1994) 1.68
Chlamydia pneumoniae and asthma. Thorax (1998) 1.67
Causes of the haemolytic uraemic syndrome. BMJ (1989) 1.66
The structural components of music perception. A functional anatomical study. Brain (1997) 1.66
The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy. Clin Pharmacokinet (1987) 1.66
N-formimidoyl-thienamycin a novel beta-lactam: an in-vitro comparison with other beta-lactam antibiotics. J Antimicrob Chemother (1981) 1.65
The effect of reserpine, an inhibitor of multi-drug efflux pumps, on the in-vitro susceptibilities of fluoroquinolone-resistant strains of Streptococcus pneumoniae to norfloxacin. J Antimicrob Chemother (1997) 1.63
Cell-autonomous expression of barley Mla1 confers race-specific resistance to the powdery mildew fungus via a Rar1-independent signaling pathway. Plant Cell (2001) 1.62
Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. Antimicrob Agents Chemother (1992) 1.62
Evaluation of a genus-specific monoclonal antibody in an amplified enzyme-linked immunoassay in the detection of Chlamydia in urine samples from men. Sex Transm Dis (1990) 1.60
SQ 26,776, a novel beta-lactam: an in-vitro comparison with other antimicrobial agents. J Antimicrob Chemother (1981) 1.60
Quinolone resistance in salmonella: clinical experience. Lancet (1990) 1.59
Bedside and rapid bacteriology. Br Med J (Clin Res Ed) (1986) 1.58
A laboratory evaluation of a novel (beta-lactam antibiotic mecillinam. J Antimicrob Chemother (1975) 1.57
Cefixime, in-vitro activity, pharmacokinetics and tissue penetration. J Antimicrob Chemother (1989) 1.57
The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group. Am Rev Respir Dis (1992) 1.53
Antimicrobial susceptibilities and beta-lactamase characterization of Capnocytophaga species. Antimicrob Agents Chemother (1992) 1.52
Specific lysis of mycobacterial antigen-bearing macrophages by class II MHC-restricted polyclonal T cell lines in healthy donors or patients with tuberculosis. Clin Exp Immunol (1990) 1.51
An assessment of the risks associated with the use of antibiotic resistance genes in genetically modified plants: report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother (2004) 1.51
In vitro and pharmacokinetic properties of the carbapenems. Antimicrob Agents Chemother (1986) 1.50
Azlocillin and mezlocillin, two new alpha-amino-substituted penicillins. A comparison of the in vitro activity with other penicillins. Arzneimittelforschung (1979) 1.49
Sch 29482--a novel penem antibiotic: an in-vitro comparison of its activity with other beta-lactams. J Antimicrob Chemother (1982) 1.49
Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J Antimicrob Chemother (2001) 1.46
A quantitative descriptive study of the prevalence of carriage (colonisation) of haemolytic streptococci groups A, B, C and G in pregnancy. J Obstet Gynaecol (2011) 1.45
Mechanisms of resistance to quinolones and clinical perspectives. J Antimicrob Chemother (1989) 1.45
Morphological and biochemical changes in Escherichia coli after exposure to ciprofloxacin. J Antimicrob Chemother (1986) 1.44
Quinolone/ureidopenicillin cross-resistance. Lancet (1987) 1.43
The pharmacokinetics of orally absorbed cefuroxime compared with amoxycillin/clavulanic acid. J Antimicrob Chemother (1984) 1.43
Pharmacokinetics and tissue penetration of azthreonam. Antimicrob Agents Chemother (1982) 1.42
Comparison of in vitro activity of FCE 22101, a new penem, with those of other beta-lactam antibiotics. Antimicrob Agents Chemother (1983) 1.42
Characteristics of Norplant users. J Obstet Gynecol Neonatal Nurs (2000) 1.41